Global Medical Device Podcast powered by Greenlight Guru

In this episode, host Etienne Nichols speaks directly to professionals in industries like automotive, aerospace, and manufacturing who are looking to transition into MedTech. Drawing from his own experience moving from aerospace to medical devices, Etienne demystifies the industry’s high barriers to entry and explains why your existing skills are more valuable than you might think.The conversation centers on the "three doors" of entry: Quality, Regulatory Affairs, and Product Development. While each path has unique requirements, Etienne emphasizes that foundational skills like project management, root cause analysis, and technical writing are the true drivers of success. He also clarifies the shift in mindset required to work in a highly regulated environment where "move fast and break things" is replaced by rigorous documentation and risk-management protocols.Finally, Etienne provides a five-step roadmap for career switchers, ranging from learning the regulatory language to networking with intention. He concludes with a powerful reminder that technical competence is only the entry fee; long-term career growth in MedTech requires mastering the "layer above"—communication, visibility, and storytelling.Key Timestamps00:00 – The "career switcher" mindset: Why MedTech is a stable and fulfilling choice.03:15 – The Regulatory Universe: Comparing IATF 16949 and AS9100 to ISO 13485 and 21 CFR Part 820.06:42 – Door #1: Quality. Roles in quality systems, auditing, and why "document control is document control."10:15 – Door #2: Regulatory Affairs. How to break into the most specialized sector of MedTech.13:50 – Door #3: Product Development. Designing with guardrails and the importance of design controls.17:30 – Transferable Skills: Project management (PMP), root cause analysis, and process validation (IQ/OQ/PQ).22:10 – What doesn't transfer: The reality of MedTech speed and the death of "good enough" thinking.26:45 – 5 Steps to making the jump: Language, credentials, networking, targeting, and honesty.32:15 – The Layer Above Competence: Navigating workplace politics and the "Workplace Poker" philosophy.Quotes"In automotive, a quality failure means a recall. In MedTech, a quality failure could mean that somebody gets hurt. It changes the math." - Etienne Nichols"If we didn't document it, it didn't happen. Getting used to that level of rigor is one of the biggest adjustments career switchers face." - Etienne NicholsTakeawaysFocus on the QMS Foundations: If you are coming from a quality background, prioritize learning ISO 13485 and ISO 14971 (Risk Management). These are the global languages of MedTech quality.Document Everything: Successful MedTech professionals must transition from "casual" documentation (emails/memos) to formal Design Controls, where every input has a verified output.Leverage Cross-Industry Skills: Lean on your experience in Six Sigma, Root Cause Analysis (RCA), and Process Validation; the statistics are the same, even if the regulatory "overlay" is different.Target Mid-Sized Companies: While big names like J&J are attractive, medium-sized companies or Contract Manufacturers (CMOs) often provide better mentorship and a faster learning curve for newcomers.Master "The Layer Above": Technical skills get you hired, but visibility and the ability to communicate technical risks to non-technical stakeholders are what lead to promotions.MedTech 101 SectionIQ/OQ/PQ (Process Validation) Think of this like baking a signature cake for a high-stakes competition.IQ (Installation Qualification): Did you plug the oven in correctly and is it the right model? (Is the equipment installed right?)OQ (Operational Qualification): Does the oven actually hit 350°F when you turn the dial, and does it stay there? (Does it work at its limits?)PQ (Performance Qualification): Can you bake ten perfect cakes in a row using your actual ingredients and staff? (Does the process consistently produce a good product?)ReferencesISO 13485:2016: The international standard for medical device quality management systems.21 CFR Part 820 / QMSR: The FDA’s requirements for medical device manufacturers.RAPS (Regulatory Affairs Professionals Society): Recommended for Regulatory Affairs Certification (RAC).Workplace Poker by Dan Rust: A recommended read for navigating office politics and career growth.Etienne Nichols' LinkedIn: Connect with Etienne hereSponsorsThis episode is brought to you by Greenlight Guru. If you are transitioning into MedTech, you'll quickly realize that documentation is everything. Greenlight Guru offers the only dedicated Quality Management System (QMS) and Electronic Data Capture (EDC) solutions designed specifically for the medical device industry. Whether you are navigating your first clinical trial or scaling a quality system from scratch, Greenlight Guru helps you move faster while staying compliant.Feedback Call-to-ActionWe want to hear your story! Are you trying to make the jump into MedTech, or have you recently made the switch? Send your questions, topic suggestions, or feedback to [email protected]. Etienne reads every email and provides personalized responses to help you on your journey. We’d also love for you to leave a review on your favorite podcast platform!

In this deep-dive episode, host Etienne Nichols shifts away from the "inspiring" fluff of entrepreneurship to deliver a gritty, practical masterclass for medical device founders. Drawing from his experience judging at MedTech Innovator and speaking with hundreds of founders, Etienne highlights a sobering reality: success in this industry isn't just about having the best technology. It is about getting the right specialized experts in the room at exactly the right time to avoid the "walls" that sink most startups.The conversation centers on the critical importance of early-stage strategic planning. Etienne argues that the most important first step for any founder isn't building a prototype or filing a patent—it’s establishing a regulatory strategy. By understanding the classification and requirements of a device early on, founders can prevent the catastrophic loss of capital and time that occurs when a design doesn't match the eventual clinical or regulatory data requirements.Finally, the episode walks listeners through the transition from design to commercialization. Etienne emphasizes the "valley of death" that occurs after FDA clearance, where many companies fail because they lacked a reimbursement strategy. This episode serves as the essential recording Etienne wishes he had ten years ago, offering a comprehensive blueprint for navigating the complex MedTech ecosystem in 2026.Key Timestamps00:01:17 - The Idea Stage: Why regulatory strategy must come before the prototype.00:03:02 - The "First Three": Essential roles for the early idea phase.00:05:35 - Stage 2: Design and Development—The reality of design controls and ISO standards.00:08:11 - Building your quality system and the necessity of risk management (ISO 14971).00:09:18 - Human Factors: Why the FDA cares about the "layperson" user experience.00:10:33 - The Manufacturing Dilemma: Why Etienne recommends a CMO over in-house production.00:14:28 - Stage 3: Testing and Verification—Managing backlogs and accredited labs.00:17:27 - The Biological Evaluation Plan: Why you need a biocompatibility expert.00:19:02 - The role of the statistician in clinical data and test methods.00:20:07 - Stage 4: Submission and Clearance—The craft of telling your regulatory story.00:22:33 - Reimbursement Strategy: The missing link that saves businesses from the "Valley of Death."00:24:07 - Stage 5: Commercialization—Navigating the post-clearance landscape.Quotes"Your regulatory pathway is going to determine everything. It determines your timeline, your budget, your clinical requirements... it's like eating your vegetables before you're even allowed to look at dessert." - Etienne Nichols"The companies that make it aren't always the ones with the best technology; they're the ones who get the right people in the room at the right time." - Etienne NicholsTakeawaysRegulatory First: Never spend significant capital on prototypes until you have a confirmed regulatory classification and pathway.Document from Day One: Start your design controls and document control early to avoid "recreating history," which is expensive, painful, and often leads to reverse engineering.Leverage CMO Expertise: In 2026, partnering with a Contract Manufacturing Organization (CMO) is often superior to in-house manufacturing due to their specialized knowledge in DFM (Design for Manufacturing) and process validation (IQ/OQ/PQ).Plan for Reimbursement Early: FDA clearance does not guarantee a business. Without a CPT code or a clear insurance coverage path, a device cannot be commercially successful.ReferencesISO 13485:2016: The international standard for medical device quality management systems.ISO 14971: The essential standard for the application of risk management to medical devices.ISO 10993: The standard series for the biological evaluation of medical devices.IEC 60601 & 62304: Standards governing electrical safety and software life cycle processes.Greenlight Guru: Provides QMS (Quality Management System) and EDC (Electronic Data Capture) solutions specifically designed for MedTech.Etienne Nichols' LinkedIn: Connect with Etienne for expert connections and industry insights.MedTech 101 SectionDesign Controls Think of design controls like a rigorous "paper trail" for a recipe. If you were baking a cake for a grocery store, you couldn't just throw ingredients in a bowl. You would need to prove what the ingredients were (Inputs), show that the final cake matches the recipe (Verification), and confirm that people actually enjoy eating it (Validation). In MedTech, this process ensures the device you built is exactly what you intended to build and that it actually helps the patient.510(k) vs. De Novo vs. PMA510(k) (Cleared): Your device is "substantially equivalent" to something already on the market (a predicate).De Novo (Granted): Your device is low-to-moderate risk, but there is no existing predicate.PMA (Approved): For high-risk, Class 3 devices (like a pacemaker). This is the most stringent path and almost always requires clinical trials.SponsorsThis episode is brought to you by Greenlight Guru. For founders navigating the design and development stage, Greenlight Guru offers a dedicated Medical Device QMS software that makes documenting design controls and risk management seamless. As you move into clinical testing, their EDC (Electronic Data Capture) solutions ensure your clinical data is high-quality and submission-ready. Align your technology with your regulatory strategy by visiting greenlight.guru.Feedback Call-to-ActionWe want to hear from you! Whether you have questions about the five stages or suggestions for a deep dive into reimbursement, send your thoughts to [email protected]. Etienne reads every email and provides personalized responses to help you on your founder journey.Did this roadmap help you? Please leave us a review on Apple Podcasts or Spotify—it helps other MedTech founders find the show!

In this episode, Etienne Nichols sits down with Staci Miller, a Human Factors and UX Strategist at GenUX, to demystify the role of human factors (HF) in the medical device regulatory pathway. Staci explains that many companies mistakenly treat HF as a "box-checking" exercise late in development, leading to costly submission delays or rejections when the FDA finds the documentation fails to tell a cohesive safety story.The conversation dives deep into the technical distinctions between a Use-Related Risk Analysis (URRA) and a User Failure Mode and Effects Analysis (uFMEA). Staci provides a framework for deciding which approach fits your product, emphasizing that while large conglomerates with post-market data may lean toward uFMEAs, startups and those with novel devices should prioritize the URRA to effectively map out user interactions without the crutch of existing market data.Finally, Staci addresses one of the most persistent myths in the industry: the idea that clinical trial data can replace human factors validation. She clarifies that while the two can overlap in specific, premeditated circumstances (such as complex implants like aortic valves), they serve entirely different masters—one focused on clinical efficacy and the other on the safety of the user interface across diverse environments.Key Timestamps04:12 – The common disconnect: Integrating Human Factors into ISO 14971 risk management.06:45 – URRA vs. uFMEA: How to choose based on your post-market data and predicate device status.10:30 – The "Definition of Done": Tracking the lifecycle of HF documentation from phase zero to market release.13:15 – System errors vs. Use errors: How to identify root causes during summative studies.18:50 – The "Clinical Trial Myth": Why efficacy data is not the same as usability validation.22:10 – Design Inputs vs. Design Outputs: The "Blueprint and the House" analogy for FDA submissions.25:40 – The impact of the "Use Environment": Testing for movement in ambulances and lighting in radiology suites.Quotes"The FDA doesn't put things out there just to have a good time... If they've made human factors a requirement and you're treating it as a 'suggestion,' you're giving yourself enough rope to hang yourself." - Staci Miller"People are obsessed with the product themselves—the design outputs. But the FDA wants to see the design inputs. They want to see the blueprints of how you built that house, not just the wallpaper." - Staci MillerTakeawaysPremeditation is Key: If you intend to use clinical trial data for HF validation, it must be planned in the protocol from the start; you cannot retroactively claim clinical data satisfies usability requirements.Map User Groups Early: Distinguish clearly between primary and secondary users. Bloating user sets without explaining how or why they engage with the device complicates your risk profile.Environment Matters: Documentation must account for the physical "10,000-foot view," including noise, lighting, and motion (e.g., an ambulance), as these are often where critical use errors occur.HF is Risk Management: Human factors should not live in a silo. It must align with the scales of harm (negligible to catastrophic) defined in ISO 14971 and work in tandem with Quality and Regulatory teams.ReferencesISO 14971: The global standard for the application of risk management to medical devices.FDA Human Factors Guidance: The primary document outlining expectations for usability testing and documentation.Etienne Nichols: LinkedIn ProfileMedTech 101: URRA vs. uFMEAThink of a uFMEA (User Failure Mode and Effects Analysis) like a car manufacturer looking at an old model to see why the brakes failed in the past—it relies on known data to fix specific parts.A URRA (Use-Related Risk Analysis) is like teaching someone to drive a brand-new type of vehicle (like a spaceship) for the first time. Since you don't have "crash data" yet, you have to carefully map out every single step the pilot takes and imagine every possible way they could push the wrong button in the heat of the moment.SponsorsGreenlight Guru: This episode is brought to you by Greenlight Guru, the only quality management platform designed specifically for the medical device industry. Whether you need to manage your QMS to stay compliant with ISO 14971 or streamline your clinical data through their EDC solutions, Greenlight Guru helps you move faster with less risk.Feedback Call-to-ActionWe want to hear from you! Do you have questions about your specific regulatory pathway or a topic you’d like us to cover? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, or suggestions to [email protected].

In this episode, Etienne Nichols sits down with regulatory expert Mike Drues, President of Vascular Sciences, to discuss the "culture shock" international medical device companies face when entering the U.S. market. They challenge the traditional assumption that a device should always launch outside the U.S. first, noting that shifting regulatory landscapes—especially in Europe—have made the U.S. a more attractive primary entry point for many.The conversation pivots to the technical and strategic nuances of "same device, different claims." Mike explains that if a device maintains the same design but utilizes different labeling or indications for use across borders, it is technically a different device in the eyes of regulators. This creates significant complexity for Quality Management Systems and post-market surveillance, particularly concerning reporting requirements for Class III (PMA) devices.Finally, the duo explores the "trap of equivalency," where companies mistakenly assume that a CE Mark or other international approval guarantees a smooth path through the FDA. From differing consensus standards to the strategic use of OUS (Outside US) clinical data, the episode provides a roadmap for global players to synchronize their regulatory and reimbursement strategies early in the development lifecycle.Key Timestamps01:45 - Challenging the assumption: Should you always launch outside the US first?04:12 - Defining the "International Company": Why every developer should think globally from day one.05:30 - The Labeling Trap: Why the same hardware with different claims is a different device.07:50 - Post-market surveillance nuances: Reporting OUS issues in a US PMA submission.11:15 - The "Sniff Test": Does a CE Mark actually help you with the FDA?12:40 - Leveraging Real-World Evidence (RWE) from international markets for US submissions.14:30 - The "Species Expansion" concept: Applying regulatory logic across different use cases.16:15 - Consensus Standards: Why the FDA might not recognize the "most current" version of a standard.20:00 - International Regulatory Strategy: Calculating the "lowest common denominator" for multi-country launches.25:20 - Using 100% OUS clinical data for FDA submissions: The three essential caveats.Quotes"If you’re marketing the same device—same design, same materials—but the labeling and claims are different in the EU versus the US, then technically, it is not the same device." - Mike Drues"The regulatory logic is agnostic of the scenario. Whether it's a label expansion or a 'species expansion' from a dog to a human, the underlying logic remains the same." - Mike DruesTakeawaysSync Your Standards: Do not assume the FDA recognizes the same version of a standard (e.g., ISO 10993-1) as international bodies. Always verify via the CDRH Recognized Consensus Standards database.Design for the "Lowest Common Denominator": Identify your top 3–5 target markets early and pool their requirements to avoid redundant benchtop or clinical testing.Rethink Clinical Trials: While the FDA prefers domestic data, OUS data can be used if you can prove the patient population and user profiles (physicians/nurses) are representative of the US demographic.Anticipate "Off-Label" Pressure: If you market a device in Canada with claims not yet approved in the US, be prepared for US clinicians to find that information online and ask for "anticipated off-label use."ReferencesFDA Recognized Consensus Standards Database: Essential tool for verifying which versions of international standards the FDA currently accepts.Greenlight Guru QMS & EDC: Solutions for managing complex, multi-region quality systems and clinical data.Etienne Nichols’ LinkedIn: Connect with the host for more MedTech insights.MedTech 101: Label ExpansionThink of Label Expansion like a smartphone software update. The hardware (the phone) stays the same, but the update allows the phone to do something it couldn't do before—like a new photography mode. In MedTech, if you have a stent approved for use in the leg (the "old label") and you want to use that same stent in the heart, you apply for a "label expansion." You aren't changing the device; you're just proving it’s safe and effective for a new job.Sponsors: Greenlight GuruThis episode is brought to you by Greenlight Guru. Navigating international waters requires a robust foundation. Greenlight Guru’s Quality Management Software (QMS) helps you maintain a "single source of truth" for your design history files and labeling, while their Electronic Data Capture (EDC) solution streamlines the collection of the clinical data you'll need to satisfy both the FDA and international regulators. Whether you are managing post-market surveillance for a PMA or running a multi-center global trial, Greenlight Guru has you covered.Feedback Call-to-ActionWe want to hear from you! Did this episode change your mind about your international launch strategy? Do you have a "culture shock" story from bringing a device to the US? Send your thoughts, reviews, or topic suggestions to [email protected]. We read every email and love providing personalized responses to our listeners.

This episode features Ivanny Franklin, Managing Partner at MedSight Capital, who brings a wealth of experience from her background in molecular biology and her decade-long tenure at NAMSA. The conversation centers on the shifting paradigms of medical device investment, specifically how the industry is moving away from service-based models toward a focus on clinical outcomes.Etienne and Ivanny explore the critical intersection of global regulatory bodies—such as the NMPA in China and the FDA in the US—and the necessity of a cohesive clinical evidence strategy. Ivanny emphasizes that for startups, understanding market-specific data requirements is not just a regulatory hurdle but a fundamental component of commercialization and investor conviction.The discussion also dives into the "patient empowerment" movement, fueled by the convergence of wearables, AI, and at-home monitoring. Ivanny shares her bullish outlook on technologies that give patients control over their data, while acknowledging the tension this creates for physicians and the ongoing need for rigorous regulatory oversight to ensure safety and effectiveness.Key Timestamps[03:15] Global Regulatory Strategy: Insights into the NMPA (formerly CFDA) and why China requires in-country clinical evidence.[07:42] Leveraging Data: How to run a single clinical trial to satisfy multiple global regulatory bodies.[10:18] The At-Home Monitoring Shift: The rise of wearables and OTC testing in the wake of COVID-19.[13:45] The "Data Gap": Addressing the friction between patient-gathered data and physician adoption.[18:22] Investment Non-Negotiables: Why revenue-generating companies and clear regulatory classifications are key for MedSight Capital.[23:10] Diligence and Deception: The importance of honesty regarding reimbursement codes and 510(k) vs. PMA paths.[27:45] SPV vs. Hedge Fund Models: A breakdown of how Special Purpose Vehicles allow family offices to be nimble in MedTech.Quotes"FDA and NMPA, for example, are quite strict in clinical evidence coming from in-country... as a startup, you really need to understand can we run a single trial with multiple global sites to achieve clearance cohesively." - Ivanny Franklin"I’m an advocate for [at-home monitoring]. I do think that’s the future. However, there is concern around what types of information should patients be receiving and how are they going to act on that information?" - Ivanny FranklinTakeawaysRegulatory is the Roadmap: An investment is often "de-risked" based on the clarity of the regulatory path. If a founder cannot distinguish between a 510(k) and a PMA, it is a major red flag for investors.Harmonize Your Trials: To achieve "economies of scale" in clinical evidence, work with consultants to design trials that meet the stringent requirements of both the FDA and international bodies like the NMPA early on.Commercial Scalability over Hype: For revenue-generating companies, investors are less concerned with the "idea" and more focused on physician retention, training, and the cost of scaling the sales team.Honesty in Reimbursement: Never "make up" or guess CPT codes. Investors utilize experts (like ex-FDA personnel) to pressure-test your reimbursement strategy during diligence.ReferencesNMPA (National Medical Products Administration): The primary regulatory body for China (formerly the CFDA).NAMSA: A world-leading Medical Device CRO mentioned as Ivanny’s former professional home.LSI (Life Science Intelligence): The upcoming conference mentioned where Etienne and Ivanny will speak on a panel.Greenlight Guru: The preferred platform for QMS & EDC solutions to manage medical device quality and clinical data.Etienne Nichols: Connect on LinkedIn.MedTech 101: SPV (Special Purpose Vehicle)Think of a Special Purpose Vehicle (SPV) like a "carpool" for investors. Instead of a massive bus (a Hedge Fund) that picks up everyone's money and decides where to go over several years, an SPV is a single car created for one specific trip—in this case, one specific company.Investors put their money into the SPV, and the SPV makes one investment in one startup. This allows smaller investors or family offices to pool their resources together to act as one large "passenger" on a company's cap table.SponsorsThis episode is brought to you by Greenlight Guru. Moving from a "service-based" model to an "outcome-based" model requires impeccable data and quality management. Greenlight Guru offers both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions designed specifically for the medical device industry. Whether you are gathering clinical evidence for an NMPA submission or scaling a revenue-generating product, Greenlight Guru helps you stay compliant and efficient.Feedback Call-to-ActionWe want to hear from you! Did this breakdown of investment vehicles help you? Do you have suggestions for future MedTech topics? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, and questions to [email protected].